Dupilumab improves long-term asthma control in German patients with severe asthma: Real-word data

<bold>Background:</bold> Although dupilumab has been approved for the treatment of severe asthma, evidence on its real-life effectiveness is still insufficient. <bold>Aims:</bold> The aim of this study was to investigate real-life effectiveness of dupilumab in patients with severe asthma. <bold>Methods:</bold> All patients from the German Asthma Network (GAN) severe asthma registry who initiated dupilumab after inclusion into the registry were analysed. Clinical effectiveness was evaluated in those with at least two follow-up visits, with maximum follow-up time currently 3 years. <bold>Results:</bold> A total of 481 patients with severe asthma initiated dupilumab. At baseline, median blood eosinophil count was 174 cells/µL (IQR 61.2-436); 184 (38.3%) were former smokers with median 9.6 pack-years (IQR 4.3-23.3). Clinical effectiveness was evaluated in 235 patients. Mean FEV1 increased from baseline statistically and clinically significantly at all timepoints (+300 mL at 4 months and 1 year, +200 mL at 2 and 3 years, all p<0.0001). The frequency of exacerbations decreased from baseline at all timepoints. Mean Asthma Control Test increased from baseline statistically and clinically significantly at all timepoints (+4.3 at 4 months, +4.9 points at 1 year, +5.3 points at 2 years, and +4.6 points at 3 years, all p<0.0001). Dupilumab was well tolerated, <10% of patients reported adverse events or discontinued dupilumab treatment. <bold>Conclusions:</bold> To our knowledge this is the largest real-life study of dupilumab in patients with severe asthma. In our cohort dupilumab, showed long-term real-life effectiveness for up to 3 years, with results consistent with prior randomised controlled trials.